Anzeige
Mehr »
Login
Sonntag, 28.05.2023 Börsentäglich über 12.000 News von 687 internationalen Medien
Bill Gates & US-Regierung Support: Der neue Hot Stock für nach Pfingsten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14W4W | ISIN: SE0007577895 | Ticker-Symbol: 6Y4
Stuttgart
26.05.23
08:14 Uhr
1,786 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VICORE PHARMA HOLDING AB Chart 1 Jahr
5-Tage-Chart
VICORE PHARMA HOLDING AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,7161,74226.05.

Aktuelle News zur VICORE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
VICORE PHARMA Aktie jetzt für 0€ handeln
03.05.Vicore begins vital endothelial dysfunction study1
30.12.22VICORE PHARMA HOLDING AB: Increase of number of shares and votes in Vicore Pharma1
08.12.22Vicore Pharma Holding AB: Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million717NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION...
► Artikel lesen
07.12.22Vicore Pharma Holding AB: Vicore intends to carry out a directed share issue389STOCKHOLM, Dec. 7, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), announces...
► Artikel lesen
03.11.22Vicore Pharma Holding AB: Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21378The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over timeVicore will accelerate clinical developmentInvitation to...
► Artikel lesen
06.10.22Vicore Pharma Holding AB: Vicore's digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study382Analyses of safety, functionality and user acceptance was positiveReported decrease in anxiety scores for patients with pulmonary fibrosisCOMPANION, a pivotal study in 250 patients with pulmonary...
► Artikel lesen
22.09.22Vicore Pharma Holding AB: Vicore announces that C21 promotes vascular function in humans333Clinically relevant doses of C21 increase blood flow in humansSystemic blood pressure was unaffected, and no side effects were observedThe forearm blood flow method is a robust technique...
► Artikel lesen
19.08.22Vicore Pharma Holding AB: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn482GOTHENBURG, Sweden, Aug. 19, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type...
► Artikel lesen
17.08.22Vicore Pharma Holding AB: Vicore IPF interim data selected as an oral "late-breaker" at the ERS congress401The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF)Interim data have shown stabilization of the disease and an increase in lung capacity...
► Artikel lesen
16.06.22Vicore Pharma Holding AB: Vicore announces first human dosed with novel ATRAG, C106360First healthy volunteer dosed with C106 in a phase 1 trialC106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore's VP03 programTopline data expected Q1 2023GOTHENBURG...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1